Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

A study reports that many VOCs are associated with impaired reduction in their susceptibility to neutralization by COVID-19 vaccines.

27 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

Study shows inhalable nanocatchers can protect lung cells against SARS-CoV-2

Inhalable nanocatchers that contain hACE2 have been recently developed by a group of researchers, providing a plethora of potential benefits in comparison to existing treatments against COVID-19.

27 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

Scientists identify an antiviral metabolite as a potential serum biomarker for SARS-CoV-2 infection

Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.

27 Jul 2021

SARS-CoV-2 interacts with unusual RNA structures in human cells

The study, published in the journal Nucleic Acids Research, demonstrated that G4 ligands, the chemical that binds with G4s, prevent this interaction. The results could pave the way for developing inhibitors of these interactions as potential antiviral compounds.

26 Jul 2021

One dose of mRNA vaccine reduced COVID risk for at least four months in health care workers

A new study compared the efficacy of mRNA vaccines against the original strain of the SARS-CoV-2 and SARS-CoV-2 VoCs among HCWs in Quebec after receiving their first and second doses.

26 Jul 2021

Budesonide’s antiviral effect against SARS-CoV-2

A new study examines the in vitro antiviral effect of pure budesonide and Pulmicort® against the SARS-CoV-2 WT and two VoCs.

26 Jul 2021

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A new study evaluates a commercially available IFN‐γ release assay (IGRA) to determine T-cell responses targeted against SARS-CoV-2.

26 Jul 2021

CDC study on efficacy of mRNA vaccines against symptomatic COVID-19

A new study posted to the medRxiv* preprint server derives measures of substantial efficacy for these vaccines in preventing mild to moderate COVID-19 from a group of outpatients with and without a history of vaccination.

26 Jul 2021

How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms

A new study published on the preprint server medRxiv* presents an analysis of the differences between recorded vaccination side effects vs. early COVID-19 symptoms. The researchers focused on four vaccines, namely, Pfizer-BioNTech (PB) mRNA (BNT162b2) vaccine, based on messenger ribonucleic acid encoding the viral spike protein; the Moderna mRNA (mRNA-1273) vaccine; the Oxford-AstraZeneca (O-AZ) adenovirus-vectored vaccine; and the Janssen adenovirus-vectored Ad26.COV2.S).

26 Jul 2021

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

COVID-19 lockdown linked to fall in early childhood vaccination in England, a rise in Scotland

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to numerous and sweeping restrictions in many countries, including the UK, limiting social and economic activity.

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

SARS-CoV-2 delta variant associated with several vaccine breakthrough cases in Houston

Their findings reveal that about 58% of all new coronavirus disease 2019 (COVID-19) cases are due to the delta variant and that the prevalence of vaccine breakthrough cases associated with the variant is as high as 20%. The study is currently available on the medRxiv* preprint server while awaiting peer review.

25 Jul 2021

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

A recent study conducted as a part of the Real-Time Assessment of Community Transmission-2 (REACT-2) program has estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among adult populations in England.

25 Jul 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Study shows inhalable nanocatchers can protect lung cells against SARS-CoV-2

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Scientists identify an antiviral metabolite as a potential serum biomarker for SARS-CoV-2 infection

SARS-CoV-2 interacts with unusual RNA structures in human cells

One dose of mRNA vaccine reduced COVID risk for at least four months in health care workers

Budesonide’s antiviral effect against SARS-CoV-2

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

CDC study on efficacy of mRNA vaccines against symptomatic COVID-19

How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms

SARS-CoV-2 antibodies in breast milk: Study

COVID-19 lockdown linked to fall in early childhood vaccination in England, a rise in Scotland

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

SARS-CoV-2 delta variant associated with several vaccine breakthrough cases in Houston

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

CoVizu: Making visual sense of variation in SARS-CoV-2 genomes

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

Activation of integrins by SARS-CoV-2 may be key to infection

Variations in human ACE2 genetics associated with coronavirus susceptibility

Industry Focus: Cell & Gene Therapy eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Industry Focus: Cell & Gene Therapy eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in